about
Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice.A structure-function approach to optimizing TLR4 ligands for human vaccinesDevelopment and function of CD94-deficient natural killer cellsNatural killer cells in NOD.NK1.1 mice acquire cytolytic function during viral infection and provide protection against cytomegalovirus.Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative.Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHCFrom mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic MechanismCD8 T cell control of HSV reactivation from latency is abrogated by viral inhibition of MHC class IInterferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of Tuberculosis.Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.Cutting edge: recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection.Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cellsMyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvantLy49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infectionAdjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization.Inhibitory Ly49 receptors on mouse natural killer cells.Natural killer cell education and tolerance.Natural killer cell licensing during viral infection.Key roles of adjuvants in modern vaccines.The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.CD94 is essential for NK cell-mediated resistance to a lethal viral disease.Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection.IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants.Assessment of Antigen-Specific Cellular Immunogenicity Using Intracellular Cytokine Staining, ELISpot, and Culture Supernatants.Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice.Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.T cell receptor revision does not solely target recent thymic emigrants.Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica.Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.AS03 stresses out macrophages: Commentary on ‘Activation of the endoplasmic reticulum stress sensor IRE1α by the vaccine adjuvant AS03 contributes to its immunostimulatory properties’.Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.αv Integrins regulate germinal center B cell responses through noncanonical autophagyEffective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses
P50
Q24817190-E043B03F-1378-463C-9FE1-DAA9EF12F2BAQ28818147-B26C5473-15CF-4606-95D5-0A4A5375B2FBQ33769518-EAE92434-3E1C-4D82-B8D6-AF109307CA82Q34115801-EC143154-9BDC-45E4-8B4C-D27C1D82C2A3Q34146613-7160154F-C94B-4212-B324-C69B68CBF7F4Q34260863-47F76764-B3C5-441C-8427-49D305B1B32AQ35127969-871063CD-36B9-4F7E-B859-3792A8E1A5F9Q35809113-9BDA810F-FF94-47EB-A292-6C2BF6297D02Q35885464-9C85C226-2BE9-48D3-8590-8CC7DE3CC257Q36075279-8ECB6D05-A4C8-4D67-9ED8-979161E0064BQ36082625-C3DADF5B-2E5B-4D88-8E10-D48AF4EC4F88Q36303844-D50B599F-0E5D-454E-A7FE-C65AC37C41E2Q36372507-4422CEB8-E733-4771-BF05-4EBF6E6C2496Q36957252-BA3EEFE7-49B2-4DA0-8521-8597D5580DB9Q37060583-446E8747-B85A-49C0-BE3B-0CF473922B40Q37218080-D5F0EEBE-CC1F-4CD1-9B90-B1443740DBBDQ37243896-1B1FA58E-ED2E-40E5-A199-A95C96F9B0B4Q37273319-2DC1FD5E-4CC5-46B3-B4CC-B1755E174270Q37410524-369C18AA-53AF-4667-BAB6-8548CAE6C8D1Q37431320-2E06025A-7CE1-4025-8A56-D3B419DA99B1Q37641418-E04C5F21-10D8-4C28-B46B-C60109FEBA10Q37777382-446A0C0A-935C-4460-A1A3-99880BC62229Q37789866-BA455B64-F285-44FC-802D-563148344C8BQ37917676-357C1603-DC46-4DB1-A0B1-4DC883C347C8Q38169040-9C12D64D-F4FD-492B-BE39-68BA9266ADF8Q38890271-2A6945D0-6EB5-4979-9A98-13ED5AEE7524Q39570193-874EABF3-E75A-4739-A968-2739E1572238Q39638076-051C54F0-D10A-4899-8F15-4F92E6520314Q39717963-5584FF7A-A134-4911-A4AE-F77B87A41784Q40476014-71AE3D10-D4C8-48CE-80A3-50718634F71BQ40513173-A8D6D76C-955C-48EB-A632-301EC0289E40Q40517477-8FDB80D4-0A70-4808-95F7-680F4F727F20Q41678523-A91E921D-7426-4309-BFD1-32F5F57A8E52Q43443359-8DB371D9-1B99-4C63-8AC1-D68C0EE67D83Q55349305-6D29C942-AA16-4B19-831B-952FDA51CCA9Q55436384-C1E8171D-0C99-4299-8BBE-16DCE43EAEB6Q55437009-D4E44823-B0D7-411E-BA25-3FF6D4962F48Q55691134-88584417-40CC-45F2-94F2-76A9AE341149Q56944872-8B22729B-795E-4331-9BB9-2F6A4BC91DB6Q56944933-524F2C75-5CEC-4997-A5E2-2AD96E4976FF
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mark T Orr
@ast
Mark T Orr
@en
Mark T Orr
@es
Mark T Orr
@nl
Mark T Orr
@sl
type
label
Mark T Orr
@ast
Mark T Orr
@en
Mark T Orr
@es
Mark T Orr
@nl
Mark T Orr
@sl
prefLabel
Mark T Orr
@ast
Mark T Orr
@en
Mark T Orr
@es
Mark T Orr
@nl
Mark T Orr
@sl
P106
P1153
7102400699
P21
P31
P496
0000-0003-2684-4722